ZA200204057B - Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions. - Google Patents

Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions. Download PDF

Info

Publication number: ZA200204057B
Authority: ZA; South Africa
Prior art keywords: medicament; production; compound; treatment; prophylaxis
Prior art date: 1999-10-27

Application number

ZA200204057A

Other languages

English (en)

Inventor

Andreas Weichert

Udo Albus

Hans Willi Jansen

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-27

Filing date

2002-05-22

Publication date

2003-02-26

2002-05-22 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2003-02-26 Publication of ZA200204057B publication Critical patent/ZA200204057B/en

Links

239000003814 drug Substances 0.000 title claims description 36
230000000302 ischemic effect Effects 0.000 title claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
201000010099 disease Diseases 0.000 title description 7
GQRRWNLARRRPRY-UHFFFAOYSA-N 1,4-dihydroquinazolin-2-amine Chemical class C1=CC=C2CNC(N)=NC2=C1 GQRRWNLARRRPRY-UHFFFAOYSA-N 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 45
238000011282 treatment Methods 0.000 claims description 27
238000004519 manufacturing process Methods 0.000 claims description 26
238000011321 prophylaxis Methods 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
206010061216 Infarction Diseases 0.000 claims description 7
230000007574 infarction Effects 0.000 claims description 7
239000000460 chlorine Substances 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
210000000056 organ Anatomy 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
230000004663 cell proliferation Effects 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
230000002093 peripheral effect Effects 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
206010002383 Angina Pectoris Diseases 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
230000000747 cardiac effect Effects 0.000 claims description 2
210000003169 central nervous system Anatomy 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
238000003860 storage Methods 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
238000002054 transplantation Methods 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims 1
230000004060 metabolic process Effects 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
238000004321 preservation Methods 0.000 claims 1
239000011734 sodium Substances 0.000 description 17
230000002265 prevention Effects 0.000 description 11
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
201000001320 Atherosclerosis Diseases 0.000 description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
239000002904 solvent Substances 0.000 description 8
210000003743 erythrocyte Anatomy 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
239000000243 solution Substances 0.000 description 6
206010048554 Endothelial dysfunction Diseases 0.000 description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000008694 endothelial dysfunction Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
208000035150 Hypercholesterolemia Diseases 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
108010062497 VLDL Lipoproteins Proteins 0.000 description 4
230000006378 damage Effects 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
230000000055 hyoplipidemic effect Effects 0.000 description 4
230000004941 influx Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000031226 Hyperlipidaemia Diseases 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 3
244000166550 Strophanthus gratus Species 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 3
229960003343 ouabain Drugs 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
208000003890 Coronary Vasospasm Diseases 0.000 description 2
208000007530 Essential hypertension Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
229960002576 amiloride Drugs 0.000 description 2
230000036523 atherogenesis Effects 0.000 description 2
230000000923 atherogenic effect Effects 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000012043 crude product Substances 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000005048 flame photometry Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
208000021822 hypotensive Diseases 0.000 description 2
230000001077 hypotensive effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
BVQIDOUXOGUAMY-UHFFFAOYSA-N (2-aminophenyl)-(3,4-dimethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=CC=CC=C1N BVQIDOUXOGUAMY-UHFFFAOYSA-N 0.000 description 1
FLORUWDSYNSEAH-UHFFFAOYSA-N (2-aminophenyl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1N FLORUWDSYNSEAH-UHFFFAOYSA-N 0.000 description 1
VSJQWMNZEHXCIX-WXXKFALUSA-N (e)-but-2-enedioate;4-(3,4-dimethoxyphenyl)-1,4-dihydroquinazolin-3-ium-2-amine Chemical compound [O-]C(=O)\C=C\C([O-])=O.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1 VSJQWMNZEHXCIX-WXXKFALUSA-N 0.000 description 1
CUMPLAGDCOPAEA-WXXKFALUSA-N (e)-but-2-enedioate;4-(3,4-dimethoxyphenyl)-3-methyl-1,4-dihydroquinazolin-3-ium-2-amine Chemical compound [O-]C(=O)\C=C\C([O-])=O.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1C.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1C CUMPLAGDCOPAEA-WXXKFALUSA-N 0.000 description 1
LGACUMPRRMLUFZ-UHFFFAOYSA-N 1,4-dihydroquinazoline Chemical compound C1=CC=C2CN=CNC2=C1 LGACUMPRRMLUFZ-UHFFFAOYSA-N 0.000 description 1
FJTWNDHPJHKMIY-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1,4-dihydroquinazolin-2-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1C2=CC=CC=C2N=C(N)N1 FJTWNDHPJHKMIY-UHFFFAOYSA-N 0.000 description 1
MMUWGLDSHWYPFG-UHFFFAOYSA-N 4-phenyl-1,4-dihydroquinazolin-2-amine Chemical compound N1C(N)=NC2=CC=CC=C2C1C1=CC=CC=C1 MMUWGLDSHWYPFG-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010010234 HDL Lipoproteins Proteins 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019668 Hepatic fibrosis Diseases 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
101710172108 Na(+)/H(+) antiporter NhaC Proteins 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
-1 antifoams Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
NTAZDTNWTTWHOM-UHFFFAOYSA-N bis[2-(2-aminophenyl)-3,4-dimethoxyphenyl]methanone Chemical compound C=1C=CC=C(N)C=1C1=C(OC)C(OC)=CC=C1C(=O)C1=CC=C(OC)C(OC)=C1C1=CC=CC=C1N NTAZDTNWTTWHOM-UHFFFAOYSA-N 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
244000309464 bull Species 0.000 description 1
230000001269 cardiogenic effect Effects 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000009693 chronic damage Effects 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
230000002727 hyperosmolar Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000009993 protective function Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200204057A 1999-10-27 2002-05-22 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions. ZA200204057B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19951702A DE19951702A1 (de)	1999-10-27	1999-10-27	Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten

Publications (1)

Publication Number	Publication Date
ZA200204057B true ZA200204057B (en)	2003-02-26

Family

ID=7927021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200204057A ZA200204057B (en)	1999-10-27	2002-05-22	Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions.

Country Status (27)

Country	Link
US (1)	US6331546B1 (et)
EP (1)	EP1244454B1 (et)
JP (1)	JP2003512420A (et)
KR (1)	KR20020041831A (et)
CN (1)	CN1181822C (et)
AR (1)	AR026242A1 (et)
AT (1)	ATE324111T1 (et)
AU (1)	AU7664800A (et)
BR (1)	BR0014985A (et)
CA (1)	CA2388965A1 (et)
CZ (1)	CZ20021414A3 (et)
DE (2)	DE19951702A1 (et)
EE (1)	EE200200215A (et)
HR (1)	HRP20020363A2 (et)
HU (1)	HUP0203774A3 (et)
IL (1)	IL149160A0 (et)
MX (1)	MXPA02004035A (et)
NO (1)	NO20021710L (et)
NZ (1)	NZ518588A (et)
PL (1)	PL356399A1 (et)
RU (1)	RU2002113667A (et)
SK (1)	SK5582002A3 (et)
TR (1)	TR200201141T2 (et)
TW (1)	TWI227135B (et)
WO (1)	WO2001030328A2 (et)
YU (1)	YU30602A (et)
ZA (1)	ZA200204057B (et)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU756437B2 (en) *	1998-08-13	2003-01-16	Agricultural Research Organization, Ministry Of Agricultural, State Of Israel	Inhibition of pathogenic processes related to tissue trauma
RS48004A (sr) *	2001-12-05	2006-10-27	Sanofi Aventis Deutschland Gmbh.	Supstituisani 4-feniltetrahidroizohinolini, postupak za njihovu proizvodnju, njihova primena u svojstvu lekova,kao i lek koji sadrži ova jedinjenja
DE10163914A1 (de) *	2001-12-22	2003-07-03	Aventis Pharma Gmbh	Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10312963A1 (de) *	2003-03-24	2004-10-07	Aventis Pharma Deutschland Gmbh	Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3560601A (en)	1968-11-25	1971-02-02	Ford Motor Co	Process for manufacturing porous thermoplastic sheet material
IL102764A0 (en) *	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
CA2146126A1 (en) *	1992-10-07	1994-04-14	Kenji Irie	Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
DE19713427A1 (de) *	1997-04-01	1998-10-08	Hoechst Ag	Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

1999
- 1999-10-27 DE DE19951702A patent/DE19951702A1/de not_active Withdrawn
2000
- 2000-10-14 SK SK558-2002A patent/SK5582002A3/sk unknown
- 2000-10-14 AU AU76648/00A patent/AU7664800A/en not_active Abandoned
- 2000-10-14 BR BR0014985-3A patent/BR0014985A/pt not_active IP Right Cessation
- 2000-10-14 WO PCT/EP2000/010127 patent/WO2001030328A2/de not_active Ceased
- 2000-10-14 EP EP00966165A patent/EP1244454B1/de not_active Expired - Lifetime
- 2000-10-14 HR HR20020363A patent/HRP20020363A2/hr not_active Application Discontinuation
- 2000-10-14 CN CNB008148872A patent/CN1181822C/zh not_active Expired - Fee Related
- 2000-10-14 HU HU0203774A patent/HUP0203774A3/hu unknown
- 2000-10-14 NZ NZ518588A patent/NZ518588A/en unknown
- 2000-10-14 PL PL00356399A patent/PL356399A1/xx unknown
- 2000-10-14 YU YU30602A patent/YU30602A/sh unknown
- 2000-10-14 RU RU2002113667/15A patent/RU2002113667A/ru not_active Application Discontinuation
- 2000-10-14 CA CA002388965A patent/CA2388965A1/en not_active Abandoned
- 2000-10-14 CZ CZ20021414A patent/CZ20021414A3/cs unknown
- 2000-10-14 EE EEP200200215A patent/EE200200215A/et unknown
- 2000-10-14 AT AT00966165T patent/ATE324111T1/de not_active IP Right Cessation
- 2000-10-14 MX MXPA02004035A patent/MXPA02004035A/es active IP Right Grant
- 2000-10-14 IL IL14916000A patent/IL149160A0/xx unknown
- 2000-10-14 TR TR2002/01141T patent/TR200201141T2/xx unknown
- 2000-10-14 DE DE50012667T patent/DE50012667D1/de not_active Expired - Lifetime
- 2000-10-14 KR KR1020027005359A patent/KR20020041831A/ko not_active Withdrawn
- 2000-10-14 JP JP2001532748A patent/JP2003512420A/ja not_active Abandoned
- 2000-10-24 TW TW089122279A patent/TWI227135B/zh not_active IP Right Cessation
- 2000-10-25 AR ARP000105620A patent/AR026242A1/es unknown
- 2000-10-26 US US09/696,233 patent/US6331546B1/en not_active Expired - Fee Related
2002
- 2002-04-11 NO NO20021710A patent/NO20021710L/no not_active Application Discontinuation
- 2002-05-22 ZA ZA200204057A patent/ZA200204057B/en unknown

Also Published As

Publication number	Publication date
EP1244454A2 (de)	2002-10-02
NO20021710D0 (no)	2002-04-11
HUP0203774A3 (en)	2003-07-28
JP2003512420A (ja)	2003-04-02
YU30602A (sh)	2004-12-31
AU7664800A (en)	2001-05-08
BR0014985A (pt)	2003-07-22
ATE324111T1 (de)	2006-05-15
NZ518588A (en)	2004-06-25
AR026242A1 (es)	2003-02-05
US6331546B1 (en)	2001-12-18
MXPA02004035A (es)	2002-10-11
PL356399A1 (en)	2004-06-28
DE50012667D1 (de)	2006-06-01
IL149160A0 (en)	2002-11-10
WO2001030328A3 (de)	2002-06-20
HUP0203774A2 (en)	2003-05-28
EE200200215A (et)	2003-06-16
CA2388965A1 (en)	2001-05-03
NO20021710L (no)	2002-04-11
TR200201141T2 (tr)	2002-11-21
DE19951702A1 (de)	2001-05-03
RU2002113667A (ru)	2004-01-10
CZ20021414A3 (cs)	2002-07-17
HK1050480A1 (en)	2003-06-27
TWI227135B (en)	2005-02-01
HRP20020363A2 (en)	2004-02-29
SK5582002A3 (en)	2002-08-06
WO2001030328A2 (de)	2001-05-03
CN1384747A (zh)	2002-12-11
CN1181822C (zh)	2004-12-29
EP1244454B1 (de)	2006-04-26
KR20020041831A (ko)	2002-06-03

Publication	Publication Date	Title
EP1515947B1 (de)	2009-09-09	Fluorierte cycloalkyl-derivatisierte benzoylguanidine und ihre verwendung als medikament
NO179673B (no)	1996-08-19	3,4,5-substituerte benzoylguanidiner og anvendelse av forbindelsene for fremstilling av legemidler
US6331546B1 (en)	2001-12-18	Use of 2-amino-3,4-dihydroquinazolines for the production of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions
RU2176638C2 (ru)	2001-12-10	Замещенные инданилидинацетилгуанидины, способ их получения, применение в качестве лекарственных или диагностических средств и лекарственные средства, содержащие эти соединения
US6291502B1 (en)	2001-09-18	Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or phophylaxis of diseases caused by ischemic conditions
RU2182901C2 (ru)	2002-05-27	Замещенные 1-нафтоилгуанидины и лекарственное средство на их основе
JP4571803B2 (ja)	2010-10-27	置換されたイミダゾリジン、その製造方法、その医薬又は診断薬としての使用、及び、置換されたイミダゾリジンを含有する医薬
SK282351B6 (sk)	2002-01-07	Orto-substituované benzoylguanidíny, spôsob ich výroby, ich použitie ako liečiva alebo diagnostického prostriedku a liečivo, ktoré ich obsahuje
HK1050480B (en)	2005-05-06	Use of 2-amino-3, 4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions
JPH1081662A (ja)	1998-03-31	ビス−オルト−置換されたベンゾイルグアニジン、その製法、医薬または診断剤としてのその使用およびそれを含有する医薬
NO309033B1 (no)	2000-12-04	Orto-substituerte benzoylguanidiner, fremgangsmÕte for fremstilling derav, anvendelse i medikament eller diagnostikk, samt medikament derav
MXPA97003871A (en)	1998-07-03	Benzoilguanidinas bis-orto-replaced, procedure for its preparation, its employment as a diagnostic medicine or agent, as well as a medication that conti
Moyssakis et al.	2006	We-P11: 225 Changes of coagulation factors and normal inhibitors of coagulation during acute phase of myocardial infarction
Dogru et al.	2006	We-P11: 226 The effect of fibrinogen and platelet aggregation on cardiovascular risk in prediabetic subjects